145 related articles for article (PubMed ID: 12481411)
1. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
de Groot FM; Broxterman HJ; Adams HP; van Vliet A; Tesser GI; Elderkamp YW; Schraa AJ; Kok RJ; Molema G; Pinedo HM; Scheeren HW
Mol Cancer Ther; 2002 Sep; 1(11):901-11. PubMed ID: 12481411
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin.
Burkhart DJ; Kalet BT; Coleman MP; Post GC; Koch TH
Mol Cancer Ther; 2004 Dec; 3(12):1593-604. PubMed ID: 15634653
[TBL] [Abstract][Full Text] [Related]
3. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
de Groot FM; van Berkom LW; Scheeren HW
J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
[TBL] [Abstract][Full Text] [Related]
5. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion.
Pedchenko V; Zent R; Hudson BG
J Biol Chem; 2004 Jan; 279(4):2772-80. PubMed ID: 14610079
[TBL] [Abstract][Full Text] [Related]
6. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
Chakravarty PK; Carl PL; Weber MJ; Katzenellenbogen JA
J Med Chem; 1983 May; 26(5):638-44. PubMed ID: 6302253
[TBL] [Abstract][Full Text] [Related]
7. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.
de Groot FM; Loos WJ; Koekkoek R; van Berkom LW; Busscher GF; Seelen AE; Albrecht C; de Bruijn P; Scheeren HW
J Org Chem; 2001 Dec; 66(26):8815-30. PubMed ID: 11749612
[TBL] [Abstract][Full Text] [Related]
8. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D.
Christensen B; Schack L; Kläning E; Sørensen ES
J Biol Chem; 2010 Mar; 285(11):7929-37. PubMed ID: 20071328
[TBL] [Abstract][Full Text] [Related]
10. L-plastin peptide activation of alpha(v)beta(3)-mediated adhesion requires integrin conformational change and actin filament disassembly.
Wang J; Chen H; Brown EJ
J Biol Chem; 2001 Apr; 276(17):14474-81. PubMed ID: 11278342
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
de Groot FM; de Bart AC; Verheijen JH; Scheeren HW
J Med Chem; 1999 Dec; 42(25):5277-83. PubMed ID: 10602713
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting α(v)β(3)/α(v)β(5) integrins and IAP proteins.
Mingozzi M; Manzoni L; Arosio D; Dal Corso A; Manzotti M; Innamorati F; Pignataro L; Lecis D; Delia D; Seneci P; Gennari C
Org Biomol Chem; 2014 May; 12(20):3288-302. PubMed ID: 24737345
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.
Ryppa C; Mann-Steinberg H; Fichtner I; Weber H; Satchi-Fainaro R; Biniossek ML; Kratz F
Bioconjug Chem; 2008 Jul; 19(7):1414-22. PubMed ID: 18578486
[TBL] [Abstract][Full Text] [Related]
14. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties.
Maeshima Y; Colorado PC; Kalluri R
J Biol Chem; 2000 Aug; 275(31):23745-50. PubMed ID: 10837460
[TBL] [Abstract][Full Text] [Related]
15. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel dual-cyclic RGD peptides for α
Liu J; Cheng X; Tian X; Guan D; Ao J; Wu Z; Huang W; Le Z
Bioorg Med Chem Lett; 2019 Apr; 29(7):896-900. PubMed ID: 30732943
[TBL] [Abstract][Full Text] [Related]
18. Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Rango E; D'Antona L; Iovenitti G; Brai A; Mancini A; Zamperini C; Trivisani CI; Marianelli S; Fallacara AL; Molinari A; Cianciusi A; Schenone S; Perrotti N; Dreassi E; Botta M
Eur J Med Chem; 2021 Nov; 223():113653. PubMed ID: 34161866
[TBL] [Abstract][Full Text] [Related]
19. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).
Zannetti A; Del Vecchio S; Iommelli F; Del Gatto A; De Luca S; Zaccaro L; Papaccioli A; Sommella J; Panico M; Speranza A; Grieco P; Novellino E; Saviano M; Pedone C; Salvatore M
Clin Cancer Res; 2009 Aug; 15(16):5224-33. PubMed ID: 19671851
[TBL] [Abstract][Full Text] [Related]
20. Development of dual-acting prodrugs for circumventing multidrug resistance.
Abu Ajaj K; Kratz F
Bioorg Med Chem Lett; 2009 Feb; 19(3):995-1000. PubMed ID: 19131246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
